Natixis Advisors
ADMA icon

Natixis Advisors’s ADMA Biologics ADMA Stock Holding History

Natixis Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,305
Closed -$345K – 1820
2026
Q1 		$345K Buy
38,305
+16,345
+74% +$258K ﹤0.01% 1626
2025
Q4 		$401K Buy
21,960
+7,894
+56% +$133K ﹤0.01% 1501
2025
Q3 		$206K Sell
14,066
-344,151
-96% -$5.9M ﹤0.01% 1621
2025
Q2 		$6.52M Buy
358,217
+321,494
+875% +$6.56M 0.01% 761
2025
Q1 		$729K Buy
36,723
+7,570
+26% +$131K ﹤0.01% 1366
2024
Q4 		$500K Buy
29,153
+11,900
+69% +$224K ﹤0.01% 1469
2024
Q3 		$345K Buy
+17,253
New +$268K ﹤0.01% 1516

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Natixis Advisors's ADMA Position: Q2 2026 in Review

Natixis Advisors sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 38,305 shares — an estimated $345K sold.

Natixis Advisors first reported a position in ADMA in Q3 2024 and held it in 7 quarters. The position peaked at $6.52M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Natixis Advisors reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Natixis Advisors sold 38,305 ADMA Biologics shares in Q2 2026, an estimated $345K.
  • Natixis Advisors first reported a position in ADMA Biologics in Q3 2024 and held it in 7 quarters.
  • Natixis Advisors's ADMA Biologics position peaked at $6.52M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.